Prophylactic Enoxaparin Reduces Symptomatic Venous Thromboembolism Compared With No Chemoprophylaxis Within 95 Days After Knee Arthroscopy.

Aylin Albrecht^1,2, Lorenz Kapral^1,2,3, Felix Gruber⁴, Christoph Dibiasi^1,2, Oliver Kimberger^1,2, Christian Albrecht^5,6

¹Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Clinical Division of General Anaesthesia and Intensive Care Medicine, Medical University of Vienna, Vienna, Austria.

²Ludwig Boltzmann Institute Digital Health and Patient Safety, Vienna, Austria.

³Department of Informatics, Research Unit Machine Learning, Technical University Vienna, Vienna, Austria.

⁴Federation of Social Insurance, Vienna, Austria.

⁵First Orthopaedic Department, Orthopedic Hospital Speising, Vienna, Austria.

⁶Michael Ogon Laboratory for Orthopedic Research, Orthopedic Hospital Vienna, Vienna, Austria.

PubMed DOI

Abstract

PURPOSE: To investigate whether prophylactic use of low-molecular-weight heparin (enoxaparin) after knee arthroscopy reduces the incidence of symptomatic venous thromboembolism (VTE) compared with no postoperative pharmacological prophylaxis. METHODS: We conducted a population-based cohort study using linked national insurance and hospital data from January 1, 2016, to December 31, 2023. Adults u…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.